Customized treatment that matches specialized cancer drugs to their
targets on each patient's tumor has been found to increase survival of
people with late-stage disease in a Phase I clinical trial at MD Anderson.
Researchers presented results today at the annual meeting of the
American Society for Clinical Oncology in Chicago. ASCO also chose to
highlight this project to the news media from among thousands
submitted to the meeting...